Cardiovascular pharmacotherapy is the cornerstone on which our approach to the management of patients with cardiovascular disease is based.
In recent years there have been a number of key breakthroughs in our treatment of cardiovascular disease. There are now highly effective antithrombotic drugs for acute and chronic coronary disease and we have a whole new category of direct anticoagulants used for stroke prevention in the patient with atrial fibrillation and for the acute and chronic management of venous thromboembolic disease. We have new highly efficacious lipid lowering therapy, and numerous studies examining cardiovascular effects of drugs used to manage diabetes. Very importantly, there has been landmark progress in the development of drugs to better address the ever-challenging problems of heart failure.
EuroCVP 2016, the 4th Annual Congress of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, will be held in Tel Aviv, Israel on 29-30 May, 2016. EuroCVP 2016 will focus on these and other key treatment breakthroughs and provide up to date discussions regarding the clinical applicability and significance of new drugs and new data. The congress will feature high quality plenary and keynote lectures, focused debates in unclear and topical areas of therapy and a large number of free communications which will be presented in e-poster and guided poster sessions.
A special attraction at ESC 2016 will be the effective and very popular ESC educational course “All About Clinical Trials”, will be held in conjunction with the main congress program. This program will give a focused view of the clinical trial arena, including trial methodology, trial challenges, trial interpretation and analysis, regulatory issues and good clinical practice.
We urge you to make every effort to attend EuroCVP 2016 and to be part of these game-changing areas in cardiovascular therapeutics.
We look forward very much to welcoming you to the vibrant and exciting city of Tel Aviv in May 2016.